Correlation of Serum Clara Cell Secretory Protein 16, Plasma Fibrinogen and Serum Amyloid A with the Severity of Acute Exacerbated COPD and Their Combination in Prognosis Assessment
Xiaojuan Hu,Jin Xu,Pei Li,Hui Zheng
DOI: https://doi.org/10.2147/COPD.S410917
2023-09-07
International Journal of COPD
Abstract:Xiaojuan Hu, 1, &ast Jin Xu, 1, &ast Pei Li, 2 Hui Zheng 3 1 Department of Pulmonary and Critical Care Medicine, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, People's Republic of China; 2 Department of Nephrology, the Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, 050004, People's Republic of China; 3 Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China &astThese authors contributed equally to this work Correspondence: Xiaojuan Hu, Department of Pulmonary and Critical Care Medicine, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, 200434, People's Republic of China, Tel +86-13524811465, Email Hui Zheng, Department of Clinical Laboratory, Fudan University Shanghai Cancer Center, Shanghai, 200032, People's Republic of China, Tel +86-18017317741, Email Introduction: Chronic obstructive pulmonary disease (COPD) has tremendous detrimental effects on patients' quality of life, lung function, disease progression and socioeconomic burden. This study aimed to investigate new serum biomarkers for COPD detection. Three recently emerging biomarkers, including Clara cell secretory protein⁃16 (CC16), plasma fibrinogen (FIB) and serum amyloid A (SAA), were investigated for their potential in stratifying the severity of COPD. Methods: A total of 220 patients with AECOPD were recruited. Multivariate logistical regression was used to analyze odds ratios of an array of characteristic of patients, including age, global initiative for chronic obstructive lung disease (GOLD), diabetes mellitus, heart diseases, PaCO2, CC16, FIB, and SAA. Correlations of CC16, FIB and SAA levels to each other, GOLD, and PaCO2 were also measured using Spearman correlation. Receiver operating characteristic (ROC)/curve analysis was used to assess sensitivity and specificity of CC16, FIB, SAA and the combination of the three markers in identifying AECOPD patients with poor prognosis. Results: Our data suggested that age, GOLD, diabetes mellitus, heart diseases, PaCO2, CC16, FIB, and SAA are all significant risk factors for poor prognosis of AECOPD. CC16, FIB and SAA were positively correlated to each other and to GOLD and PaCO2 levels. CC16, FIB and SAA all had a high sensitivity and specificity in identifying patients with a poor prognosis. CC16, FIB and SAA are new markers with potentially high predictive value in AECOPD. Discussion: Our data support further development of these biomarkers to improve clinical management of AECOPD through providing more accurate prognosis of AECOPD patients that enable timely adjustment of treatment plans. Keywords: AECOPD, CC16, FIB, SAA Chronic obstructive pulmonary disease (COPD) has tremendous detrimental effects on patients' quality of life, lung function, disease progression and socioeconomic burden. 1 COPD is known to be triggered by cold weather, pollutants, or irritants and exacerbated by acute respiratory tract infection. 2 Patients in the acute phase of COPD, acute exacerbation COPD (AECOPD), suffer from elevated airway inflammation, 3 which in turn progresses into bronchial mucosal congestion and edema, excessive mucus secretion, smooth muscle spasm, and aggravates airway narrowing, leading to restricted expiratory airflow and dynamic hyperinflation of the lungs. Patients may also experience acute changes in shortness of breath, cough or sputum, demanding abrupt change of treatment strategies. As a result, acute exacerbation symptoms could occur, and may lead to a systemic inflammatory response. 4 Despite recent advancement in AECOPD treatment, the overall efficacy of AECOPD treatment is still unsatisfactory. There is a pressing unmet need to develop simple but efficient physiological indicators to assess the prognosis of patients with AECOPD, and to take corresponding measures for intervention and treatment to improve the prognosis of patients. 5 Serum biomarkers are favored diagnostic tools owing to their cost-effectiveness and convenience. Emerging studies demonstrated a few serum biomarkers, such as C-reactive protein (CRP), 6 I-FABP, citrulline, D-Lactate, DAO, and α-GST 7 as biomarkers with predictive value in terms of readmission. However, the sensitivity and specificity of the biomarkers remain unsatisfactory. For example, a previous study demonstrated that CRP could achieve a sensitivity of 74.5% and specificity of 81% for readmission events among AECOPD patients. 6 Among new biomarkers investigated, serum amyloid A (SAA), which is a polygenic encoded acu -Abstract Truncated-
respiratory system